Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis versus Eylea with mfPOP monitoring in wet age-related macular degeneration
ACTRN12614000497606Phase 3Recruiting
- Sponsor
- Australian National University
- Start
- Jan 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in exudative macular degeneration comparing Eylea arm with Lucentis arm (2 arms). Primary endpoint: Multifocal objective pupil perimetry measures of macular function. Started Jan 2015; status: recruiting.
02
Drugs
ranibizumabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ACTRN12614000497606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000497606.